Plasma inflammatory and edema-related proteins

Plasma inflammatory and edema-related proteins constitute a diverse group of circulating molecules that mediate systemic immune responses and regulate vascular permeability. This category encompasses various protein families, including cytokines such as TNF-alpha and IL-6, chemokines, and components of the kallikrein-kinin and complement systems (Source: PubMed, PMID: 28249924). These proteins are essential for physiological processes like wound healing and pathogen defense, but their overactivation is linked to diseases such as hereditary angioedema, sepsis, and chronic inflammatory disorders (Source: NIH, StatPearls - Angioedema). In drug development, this term often refers to a panel of biomarkers used to assess the inflammatory state of a patient or the pharmacodynamic effect of a drug (Source: Olink Proteomics). Many individual proteins within this group are established therapeutic targets, with drugs like infliximab and lanadelumab specifically designed to inhibit their activity. Because this is a collective term for multiple distinct proteins, it is primarily used in the context of proteomic profiling and clinical diagnostics rather than as a single drug-binding site (Source: PubMed, PMID: 32531081).

Other names

Inflammatory biomarkersEdema mediatorsPlasma proteome inflammatory panelVascular permeability factors

Drugs targeting these proteins typically act through monoclonal antibody-mediated neutralization of cytokines, competitive inhibition of proteases like plasma kallikrein, or antagonism of specific G protein-coupled receptors to reduce vascular permeability and systemic inflammation.